Form 4: Erasca Director Acquires Stock Options in Lieu of 2025 Cash Compensation

Valerie Denise Harding, a director at Erasca, Inc., acquired 29,402 stock options in lieu of cash compensation for her board service in 2025.

Summary

• Valerie Denise Harding, a director of Erasca, Inc., has acquired 29,402 stock options.
• These options were granted in lieu of cash compensation for her service on the board of directors and its committees in 2025.
• The options have an exercise price of $2.51 per share.
• The options will vest in monthly increments over a 12-month period, starting one month from the grant date, contingent on her continued service on the board.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of stock options being granted to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The acquisition of stock options by a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Management Comments

• The option grant was issued in lieu of cash compensation payable to the director in 2025.
• The options will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date.

Industry Context

It is common practice for companies to compensate board members with stock options to align their interests with shareholders and incentivize long-term value creation. This is a standard form 4 filing for a director.

Comparison to Industry Standards

• Granting stock options to board members is a common practice across the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of monthly increments over 12 months is also a typical approach to ensure continued service and commitment from board members.
• The exercise price of $2.51 is specific to Erasca's stock and its valuation at the time of the grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better decision-making.
• The vesting schedule encourages the director's continued service on the board.

Key Dates

Keywords

stock options, director compensation, insider trading, board of directors, equity, Erasca